RxDoctor Payments Data

Craig Mueller

Nurse Practitioner · Wake Village, TXNPI 1164448155

Payments from drug & device makers

$7,532in general payments, 2019–2025

Across 571 payments — averaging $13.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$904
  • Novo Nordisk$609
  • Pfizer$603
  • Amgen$365
  • Merck$365
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$7,514100%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,532 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$124,421
Medicare patients
414
Services billed
4,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$118,795
MounjaroTirzepatide90$105,017
EliquisApixaban117$89,701
FarxigaDapagliflozin Propanediol89$82,806
JardianceEmpagliflozin41$50,113
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,618
EntrestoSacubitril/Valsartan17$18,904
XareltoRivaroxaban17$18,759
TrulicityDulaglutide13$18,716
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$16,610
Repatha SyringeEvolocumab20$11,628
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,415
Spiriva RespimatTiotropium Bromide11$5,505
SymbicortBudesonide/Formoterol Fumarate14$4,540
Desvenlafaxine Succinate ErDesvenlafaxine Succinate71$3,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$904$123,732103 claims
Novo NordiskOzempic$609$118,795123 claims
PfizerEliquis$603$89,701117 claims
AstraZenecaFarxiga, Symbicort$245$87,345103 claims
Boehringer IngelheimJardiance, Spiriva Respimat$160$55,61852 claims
GSKTrelegy Ellipta$185$22,61829 claims
NovartisEntresto$211$18,90417 claims
Johnson & JohnsonXarelto$146$18,75917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Wake Village

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →